A clinical trial indicated that lower serum ACE2 levels correlated with higher postoperative morbidities and in‐hospital mortality ratios after surgery of major pulmonary resection in non‐small cell lung cancer (NSCLC) patients.5 Here, ACE2 is linked to lung cancer.